Citadel Advisors
GPCR icon

Citadel Advisors’s Structure Therapeutics GPCR Stock Holding History

Citadel Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-772,518
Closed -$52.9M – 13457
2025
Q4 		$53.7M Buy
772,518
+328,718
+74% +$13.4M 0.01% 1344
2025
Q3 		$12.4M Sell
443,800
-884,679
-67% -$17.6M ﹤0.01% 2940
2025
Q2 		$27.6M Buy
1,328,479
+336,139
+34% +$7.39M ﹤0.01% 1782
2025
Q1 		$17.2M Sell
992,340
-486,999
-33% -$11.9M ﹤0.01% 2204
2024
Q4 		$40.1M Buy
1,479,339
+27,841
+2% +$988K 0.01% 1472
2024
Q3 		$63.7M Buy
1,451,498
+43,113
+3% +$1.67M 0.01% 1016
2024
Q2 		$55.3M Buy
1,408,385
+132,523
+10% +$5.44M 0.01% 1073
2024
Q1 		$54.7M Buy
1,275,862
+122,877
+11% +$5.18M 0.01% 1139
2023
Q4 		$47M Buy
1,152,985
+72,393
+7% +$4.15M 0.01% 1245
2023
Q3 		$54.5M Buy
1,080,592
+730,929
+209% +$23.6M 0.01% 1004
2023
Q2 		$14.5M Sell
349,663
-16,624
-5% -$466K ﹤0.01% 2217
2023
Q1 		$8.71M Buy
+366,287
New +$8.61M ﹤0.01% 2989

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Citadel Advisors's GPCR Position: Q1 2026 in Review

Citadel Advisors sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 772,518 shares — an estimated $52.9M sold.

Citadel Advisors first reported a position in GPCR in Q1 2023 and held it in 12 quarters. The position peaked at $63.7M in Q3 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Citadel Advisors reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 772,518 Structure Therapeutics shares in Q1 2026, an estimated $52.9M.
  • Citadel Advisors first reported a position in Structure Therapeutics in Q1 2023 and held it in 12 quarters.
  • Citadel Advisors's Structure Therapeutics position peaked at $63.7M in Q3 2024.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.